Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 37, 4297-4303, December 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chello, P. L.
Right arrow Articles by Donsbach, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chello, P. L.
Right arrow Articles by Donsbach, R. C.

Therapeutic Relevance of Differences in the Structural Specificity of the Transport Systems for Folate Analogs in L1210 Tumor Cells and in Isolated Murine Intestinal Epithelial Cells1

Paul L. Chello2, Francis M. Sirotnak, Diane M. Dorick and Ruth C. Donsbach

Memorial Sloan-Kettering Cancer Center, New York, New York 10021

The kinetics of aminopterin, methotrexate (10-methylaminopterin), and 10-ethylaminopterin transport by isolated murine intestinal epithelial cells was determined and compared with that of L1210 tumor cells. The Michaelis constant (Km) for the influx of aminopterin into L1210 tumor cells was 1.2 µM, as contrasted to 7.2 µM for influx into isolated intestinal epithelial cells. Substitution of a methyl or an ethyl moiety at position 10 of the aminopterin molecule reduced the affinity (increased the Km) of the L1210 carrier system for either derivative approximately 3-fold. In contrast, the affinity of the carrier system of isolated intestinal epithelia for methotrexate or for 10-ethylaminopterin was 12- and 17-fold less than that for aminopterin. The rate of efflux of each of the folate analogs within a particular cell type was approximately the same; efflux was approximately 3 times slower from isolated intestinal epithelial cells than from L1210 cells.

Following the s.c. administration of aminopterin (3.0 mg/kg) to mice bearing L1210 ascites, levels of drug in excess of that bound to dihydrofolate reductase were maintained in both small intestine and L1210 cells for at least 24 hr. After 3.0 mg/kg s.c., levels of methotrexate or of 10-ethylaminopterin in excess of that bound to dihydrofolate reductase were maintained for only 4 to 6 hr in small intestine but for 16 to 24 hr in L1210 tumor cells. Therapy trials in which a s.c. dose was given every other day until death confirmed that the optimum dose range for aminopterin (0.15 to 0.3 mg/kg) was lower than that for either methotrexate (6 to 9 mg/kg) or 10-ethylaminopterin (6 to 9 mg/kg) and that the increase in life span at the maximum tolerated range was higher for the derivatives substituted at position 10 (150 to 180%) than it was for aminopterin (75%).

The higher affinity of the carrier system in tumor cells as compared to that of the carrier system in normal cells for each folate analog results in a greater persistence of drug in tumor in vivo and explains the selective antitumor action of each of the three analogs. Substitution at position 10 of aminopterin reduces the affinity of the transport system in both tumor and normal cells for these drugs, but to a different extent. The greater reduction in the affinity of the carrier in normal cells than in tumor cells accounts for the improved therapeutic index of both the methyl and the ethyl-substituted derivatives.

1 Supported in part by Grants CA-16153 and CA-08748 from the National Cancer Institute and Grant CH-26 from the American Cancer Society.

2 To whom requests for reprints should be addressed.

Received 5/12/77. Accepted 8/24/77.




This article has been cited by other articles:


Home page
Cancer Res.Home page
T. M. Trippett, S. Garcia, K. Manova, R. Mody, L. Cohen-Gould, W. Flintoff, and J. R. Bertino
Localization of a Human Reduced Folate Carrier Protein in the Mitochondrial as Well as the Cell Membrane of Leukemia Cells
Cancer Res., March 1, 2001; 61(5): 1941 - 1947.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
C. D. Chancy, R. Kekuda, W. Huang, P. D. Prasad, J.-M. Kuhnel, F. M. Sirotnak, P. Roon, V. Ganapathy, and S. B. Smith
Expression and Differential Polarization of the Reduced-folate Transporter-1 and the Folate Receptor alpha in Mammalian Retinal Pigment Epithelium
J. Biol. Chem., June 30, 2000; 275(27): 20676 - 20684.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1977 by the American Association for Cancer Research.